propionamide has been researched along with Neoplasms in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (66.67) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Gassner, C; Kniess, T; Laube, M; Pietzsch, J | 1 |
Dobs, AS; Zilbermint, MF | 1 |
Dumont, F; Foidart, JM; Frankenne, F; Lejeune, A; Oltenfreiter, R; Slegers, G; Staelens, L | 1 |
1 review(s) available for propionamide and Neoplasms
Article | Year |
---|---|
Nonsteroidal selective androgen receptor modulator Ostarine in cancer cachexia.
Topics: Amides; Anilides; Cachexia; Clinical Trials as Topic; Humans; Neoplasms; Receptors, Androgen | 2009 |
2 other study(ies) available for propionamide and Neoplasms
Article | Year |
---|---|
Synthesis and Cyclooxygenase Inhibition of Sulfonamide-Substituted (Dihydro)Pyrrolo[3,2,1-
Topics: Amides; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Design; Humans; Hydrophobic and Hydrophilic Interactions; Indoles; Neoplasms; Prodrugs; Structure-Activity Relationship; Sulfonamides | 2019 |
New radioiodinated carboxylic and hydroxamic matrix metalloproteinase inhibitor tracers as potential tumor imaging agents.
Topics: Amides; Animals; Biomarkers, Tumor; Feasibility Studies; Iodine Radioisotopes; Isotope Labeling; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Metabolic Clearance Rate; Mice; Neoplasms; Organ Specificity; Propionates; Radionuclide Imaging; Radiopharmaceuticals; Tissue Distribution | 2004 |